Biomaterials Science Submission Guide

Source: Clarivate JCR 2024, RSC editorial disclosures (accessed April 2026).

Source: Biomaterials Science author guidelines.

Use this page when deciding:

• whether the biomaterials contribution is substantive

• whether biological characterization is rigorous

• whether biomaterials framing is articulated

• a clear biomaterials contribution

• rigorous biological characterization

• biomaterials framing

• material-property linkage

• a cover letter establishing the contribution

• Descriptive biomaterials studies without application.

• Weak biological characterization.

• Missing biomaterials framing.

• General materials research without biomaterials focus.

Biomaterials Science is a flagship biomaterials journal.

Biomaterials-application standard: the journal differentiates from broader materials venues by demanding biomaterials contributions.

Biological-characterization expectation: editors expect in vitro or in vivo validation.

The 30-40% desk rejection rate: decisive editorial screen.

The strongest Biomaterials Science editor-facing notes establish:

• the biomaterials contribution

• the biological characterization

• the biomaterials framing

• the central finding

Biomaterials Science requires these at first submission:

• main manuscript file in RSC format with graphical abstract embedded

• cover letter establishing the biomaterials advance and biological-application relevance

• TOC graphic with one-sentence summary of the biomaterials advance

• author byline with ORCID iDs for the Corresponding Author (recommended for all co-authors)

• competing-interests declaration

• ethics statement for any animal or human-cell work (institutional approval references)

• data availability statement covering material synthesis data, cell-culture data, in vivo data, and any imaging or characterization datasets

• supporting information PDF (compiled separately)

• for Communications, a brief paragraph in the cover letter justifying the importance and urgency that warrants the rapid-publication track

• for Review proposals, a completed Review Proposal Form assessed by the Editor-in-Chief; approved proposals receive a personalized submission link

• declaration of generative AI use in the writing process

• for revised submissions, point-by-point reviewer response and marked-up manuscript

For Biomaterials Science submissions, the most common artifact-related issue is missing or weak biological-characterization data on materials-focused submissions. The journal title is "Biomaterials Science" rather than "Biomaterials Engineering"; editors expect the biology to be in the package at first submission, not promised as future work. Submissions with strong material synthesis but only cytotoxicity data face routine major-revision or rejection requests for in vitro or in vivo functional evidence.

Biomaterials Science manuscripts move through a four-stage editorial timeline. The journal's published 37-day first-decision target compresses the workflow relative to slower RSC journals.

Day 0 to 5: ReView intake and technical check

The platform performs format and declaration checks. Editorial staff verify the cover letter, ethics statement, data availability statement, and TOC graphic. For Communications, the editorial team specifically reviews the importance justification.

Day 5 to 14: Editor-in-Chief or Associate Editor desk-screen

An Editor (the Editor-in-Chief (listed on the journal's editorial-team page; verify before quoting) or a delegated Associate Editor matched to tissue engineering, drug delivery, biointerfaces, or biomedical devices) reviews scope fit, novelty, and the balance of materials work and biological characterization. Materials-only submissions are routinely transferred via RSC's editorial network to RSC Materials Advances or Journal of Materials Chemistry B.

Week 2 to 6: External peer review

Manuscripts that pass desk-screen go to 2-3 reviewers selected for materials and biology expertise. Reviewer turnaround supports the 37-day median first-decision target.

Week 6 to 14: Decision and revision rounds

First decisions arrive at the 4-6 week median (publisher reports 37 days), typically as major or minor revision. Revision cycles add 4-8 weeks.

• Is Biomaterials Science a good journal?

• Acta Biomaterialia Submission Guide for biomaterials manuscripts where the biological response, tissue interaction, or in vivo validation package needs a higher-selectivity biomaterials venue.

Before upload, run your manuscript through a Biomaterials Science check.

The sources above define the mechanics; the harder question is whether this draft earns review. The review tells you whether your paper clears the Biomaterials Science fit check before upload, especially around descriptive biomaterials studies without application, weak biological characterization, and missing biomaterials framing. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.

Across biomaterials manuscripts targeting Biomaterials Science, three recurring patterns explain the majority of desk rejections.

Manusights pre-submission pattern analysis shows many Biomaterials Science desk rejections trace to descriptive biomaterials studies. The same pattern analysis often finds these cases involve weak biological characterization. A related pattern is that these cases often arise from missing biomaterials framing.

Descriptive biomaterials studies without application

Editors look for biological-application advances. We observe submissions framed as material descriptions routinely desk-rejected.

Check descriptive biomaterials studies without application before submitting to Biomaterials Science →

Weak biological characterization

Editors expect in vitro or in vivo validation. We see manuscripts with thin biological data routinely returned.

Check weak biological characterization before submitting to Biomaterials Science →

Missing biomaterials framing

Biomaterials Science specifically expects biomaterials focus. We find papers framed as general materials without biomaterials positioning routinely declined. A Biomaterials Science check can identify whether the package supports a submission.

Clarivate JCR 2024 bibliometric data places Biomaterials Science among top biomaterials journals.

Check missing biomaterials framing before submitting to Biomaterials Science →

In pre-submission diagnostic work for top biomaterials journals, we consistently see four signals that distinguish strong submissions from weak ones. First, the contribution must be application-oriented. Second, biological characterization should be rigorous. Third, biomaterials framing should be primary. Fourth, material-property linkage should be established.

For Biomaterials Science-targeted manuscripts, the single most consistent feedback class we deliver in pre-submission diagnostics for Biomaterials Science is the descriptive-versus-application distinction. Editors expect application contributions. Submissions framed as "we synthesized material X" without biological application routinely receive "where is the application?" feedback. We coach authors to lead with the application question.

For Biomaterials Science-targeted manuscripts, beyond the rubric checks, three pre-submission diagnostic patterns recur most often in the manuscripts we review for Biomaterials Science. First, manuscripts where the abstract reports synthesis without biological characterization are flagged. Second, manuscripts where biological assays lack controls are flagged. Third, manuscripts that lack engagement with Biomaterials Science's recent issues are flagged.

The Biomaterials Science submissions we coach toward acceptance distinguish themselves on three operational behaviors. First, the cover letter names a translational endpoint (clinical indication, regulatory pathway, or named patient population) within the first 80 words rather than ending vaguely on "biomedical applications." Second, the figure layout reserves one of the early main-text figures (often Figure 2) for the biological-functional result rather than placing all biology in the supplementary.

Third, the discussion explicitly compares the new biomaterial to at least two recent Biomaterials Science papers that addressed the same clinical problem from different chemistries.

Editorial triage at Biomaterials Science operates on limited time per manuscript. Editors typically scan abstract, introduction, methodology, and conclusions before deciding whether to invite reviewer engagement. We coach researchers to design abstract, introduction, and conclusions for fast assessment.

Beyond methodology and contribution, Biomaterials Science weights author-team authority within the biomaterials subfield. Strong submissions reference Biomaterials Science's recent papers explicitly.

For Biomaterials Science-targeted manuscripts, beyond methodology and contribution, journals at this tier increasingly reward submissions that explicitly position the work within a specific subfield conversation rather than treating the literature as undifferentiated.

For Biomaterials Science specifically, three desk-rejection patterns recur in our pre-submission reviews. First, materials-only papers with deferred biology ("biological evaluation underway, will be added at revision") are treated as out-of-scope rather than as work-in-progress. Second, in vivo claims supported by a single small-animal cohort without sample-size justification fail the editorial-rigor check. Third, biomaterial-device papers that do not engage with the FDA / EMA regulatory pathway in the discussion are flagged as incomplete for a journal that emphasizes translation toward clinical use.

Before any Biomaterials Science submission, we walk authors through a journal-specific pre-flight checklist that mirrors what the Editor and reviewers will actually look for:

• the cover letter names a clinical or translational endpoint within the first paragraph

• the abstract reports at least one biological-functional outcome alongside the materials characterization

• in vitro evidence uses a cell line or primary cell type relevant to the claimed application (not just NIH/3T3 or HeLa unless the indication justifies it)

• any in vivo data uses sample sizes justified by a power calculation

• the discussion engages the FDA or EMA regulatory pathway if the work claims translational relevance

• the recent-literature engagement section names at least three Biomaterials Science papers from the past 24 months on the same target indication